Lung Cancer
Volume 65, Issue 2 , Pages 192-197 , August 2009

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

  • Mark J. McKeage

      Affiliations

    • Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Rd, Grafton, Private Bag 92019, Auckland 1142, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64 9 3737 599x87322; fax: +64 9 3737 556.
    • ,
  • Martin Reck

      Affiliations

    • Krankenhaus Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
    • ,
  • Michael B. Jameson

      Affiliations

    • Waikato Hospital, Private Bag 3200, Hamilton, New Zealand
    • ,
  • Mark A. Rosenthal

      Affiliations

    • Royal Melbourne Hospital, Melbourne 3050, Australia
    • ,
  • David Gibbs

      Affiliations

    • Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand
    • ,
  • Paul N. Mainwaring

      Affiliations

    • Mater Health Services, Brisbane, QLD 4101, Australia
    • ,
  • Lutz Freitag

      Affiliations

    • Lungenklinik Hemer, Theo-Funccius-Str. 1, D-58675 Hemer, Germany
    • ,
  • Richard Sullivan

      Affiliations

    • Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand
    • ,
  • Joachim Von Pawel

      Affiliations

    • Asklepios Fachkliniken, Robert-Koch-Allee 2, D-82131 Gauting, Germany

Received 15 January 2009 ,Revised 26 March 2009 ,Accepted 28 March 2009.

References 

  1. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423–435
  2. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  4. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  5. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408–3416
  6. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003;21:2815–2822
  7. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21:4428–4438
  8. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003;4:141–148
  9. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 2002;86:1937–1942
  10. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 1999;59:3304–3307
  11. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer. 2004;90:906–910
  12. Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995;71:1204–1209
  13. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res. 1994;6:79–85
  14. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer. 2003;88:1844–1850
  15. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer. 2003;88:1160–1167
  16. McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res. 2006;12:1776–1784
  17. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res. 1997;9:55–60
  18. McKeage MJ, Kestell P, Denny WA, Baguley BC. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol. 1991;28:409–413
  19. McKeage MJ, Kelland LR. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA); clinical potential in combination with taxane-based chemotherapy. Am J Cancer. 2006;5:155–162
  20. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1997;39:541–546
  21. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol. 2003;51:43–52
  22. Gabra H, Jameson M. AS1404-202 study group investigators update of phase II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in recurrent ovarian cancer. Eur J Cancer Suppl. 2007;5(4):319
  23. Pili R, Rosenthal M. AS1404-203 study group investigators. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol. 2008;26(May (Suppl.)):5007;[abstract]
  24. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008;99:2006–2012
  25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  26. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–1756
  27. Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, et al. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res. 2006;12:7406–7413
  28. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004;10:96–100
  29. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  30. Scagliotti G, von Pawel J, Reck M, Cupit L, Cihon F, Dimatteo S, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV nonsmall cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, doubleblind, placebo-controlled, ESCAPE (evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial. Late breaking abstract presented at 1st European Lung Cancer Conference 2008.

PII: S0169-5002(09)00206-2

doi: 10.1016/j.lungcan.2009.03.027

Lung Cancer
Volume 65, Issue 2 , Pages 192-197 , August 2009

Article Tools

* Image Usage & Resolution